{"created":"2023-08-02T03:58:13.856257+00:00","id":7391,"links":{},"metadata":{"_buckets":{"deposit":"b6cc8b8c-164e-43ce-8342-14092e919e37"},"_deposit":{"created_by":10,"id":"7391","owners":[10],"pid":{"revision_id":0,"type":"depid","value":"7391"},"status":"published"},"_oai":{"id":"oai:repository.lib.tottori-u.ac.jp:00007391","sets":["1:7","2:12"]},"author_link":["4880","27500"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-11-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"41","bibliographicPageStart":"31","bibliographicVolumeNumber":"110","bibliographic_titles":[{"bibliographic_title":"Vascular Pharmacology"},{"bibliographic_title":"Vascular Pharmacology","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Sorafenib reverses pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR), but the effects of toceranib are unknown. This study investigated anti-remodeling effects and determined optimal doses of toceranib and sorafenib on monocrotaline (MCT)-induced PAH and CPR in rats. MCT-treated rats were orally treated with a 14-day course of sorafenib (10, 30, or 100 mg/kg), toceranib (1, 3, or 10 mg/kg), or water. Both sorafenib and toceranib significantly reversed the right ventricular (RV) hypertrophy at 10 mg/kg, but only sorafenib significantly improved the RV systolic and mean pressures. Sorafenib significantly normalized the B-type natriuretic peptide mRNA level of the RV and increased the non-muscularized pulmonary artery percentage. However, these effects were only observed at the highest toceranib dose, and neither toceranib dose reduced the fully muscularized pulmonary artery percentage. Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Besides the stronger inhibition on mitogen-activated protein kinase signaling, the greater reversal ability of sorafenib may be also due to the simultaneous blockade on the C-X-C chemokine receptor type 4 and autophagy induction. Toceranib insignificantly reversed CPR, and a high-dose therapy did not improve the RV hemodynamic outcomes. Sorafenib significantly reversed CPR, and a low-dose sorafenib therapy may be a suitable therapeutic agent for PAH.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.vph.2018.07.002","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_16":{"attribute_name":"情報源","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"Leong, Zi Ping. Hikasa, Yoshiaki. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats. Vascular Pharmacology. 110. 31-41. 2018. doi:10.1016/j.vph.2018.07.002"}]}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://www.sciencedirect.com/science/article/pii/S1537189118302192"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.sciencedirect.com/science/article/pii/S1537189118302192","subitem_relation_type_select":"URI"}}]},"item_10001_rights_15":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"(C) 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"15371891","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_33":{"attribute_name":"著者所属（英）","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"The United Graduate School of Veterinary Science, Yamaguchi University"},{"subitem_text_language":"en","subitem_text_value":"The United Graduate School of Veterinary Science, Yamaguchi University / Joint Department of Veterinary Medicine, Laboratory of Veterinary Internal Medicine, Tottori University"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"日笠, 喜朗"},{"creatorName":"ヒカサ, ヨシアキ","creatorNameLang":"ja-Kana"},{"creatorName":"Hikasa, Yoshiaki","creatorNameLang":"en"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Leong, Zi Ping","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-03-17"}],"displaytype":"detail","filename":"vp110_31.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensefree":"(C) 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"vp110_31.pdf","url":"https://repository.lib.tottori-u.ac.jp/record/7391/files/vp110_31.pdf"},"version_id":"648b09c4-dc08-4a84-a2be-bae5c9344585"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cardiopulmonary remodeling","subitem_subject_scheme":"Other"},{"subitem_subject":"Pulmonary arterial hypertension","subitem_subject_scheme":"Other"},{"subitem_subject":"Right ventricular hypertrophy","subitem_subject_scheme":"Other"},{"subitem_subject":"Sorafenib","subitem_subject_scheme":"Other"},{"subitem_subject":"Toceranib","subitem_subject_scheme":"Other"},{"subitem_subject":"Cardiopulmonary remodeling","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pulmonary arterial hypertension","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Right ventricular hypertrophy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Sorafenib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Toceranib","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article"}]},"item_title":"Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"10","path":["12","7"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-09-08"},"publish_date":"2022-09-08","publish_status":"0","recid":"7391","relation_version_is_last":true,"title":["Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats"],"weko_creator_id":"10","weko_shared_id":-1},"updated":"2023-11-22T01:51:39.763684+00:00"}